Breaking News, Collaborations & Alliances

Transpire Bio Inks Second Agreement with Recipharm

Will develop two additional inhaled medicines.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has entered a second agreement with Recipharm to develop TRB-3 and TRB-4, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). TRB-3 and TRB-4, marking the rapid progression of the Transpire Bio pipeline, are inhaled products being developed for advanced markets. With a focus on streamlining the development process...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters